Published in Bone Marrow Transplant on December 10, 2012
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia (2015) 1.03
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia (2015) 0.93
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front Pediatr (2014) 0.92
The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling. Bone Marrow Transplant (2013) 0.89
Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant (2014) 0.81
Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism. Bone Marrow Transplant (2014) 0.76
Transplantation of human umbilical cord mesenchymal stem cells in cochlea to repair sensorineural hearing. Am J Transl Res (2016) 0.75
Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis. Case Rep Hematol (2016) 0.75
Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease. Bone Marrow Transplant (2013) 0.75
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Physiological migration of hematopoietic stem and progenitor cells. Science (2001) 7.02
Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant (2009) 6.22
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant (2009) 2.03
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood (2003) 1.72
Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplant (2009) 1.52
Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. Blood (2002) 1.45
Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Blood (1999) 1.20
Laparoscopic splenectomy: outcomes and lessons learned from over 200 cases. Surgery (2000) 1.20
Distribution of marrow repopulating cells between bone marrow and spleen early after transplantation. Blood (2003) 1.09
The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant (2010) 1.06
The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica (2006) 1.01
Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood (2001) 1.01
Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. Br J Haematol (2010) 0.91
Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia (2001) 0.90
Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation (1985) 0.89
Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev (1999) 0.85
Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant (1990) 0.84
Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia. Lancet (1985) 0.84
Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: the influence of previous splenectomy. Br J Haematol (1984) 0.83
Splenectomy and bone marrow transplantation in chronic granulocytic leukaemia. Lancet (1983) 0.83
Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Leukemia (1996) 0.83
Splenectomy may reverse pancytopenia occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant (1994) 0.83
Recovery from radiation injury with and without bone marrow transplantation: effects of splenectomy. Radiat Res (1970) 0.78
Reduced transfusion requirements in a splenectomized patient undergoing bone marrow transplantation. Acta Haematol (1994) 0.78
Experimental studies on role of spleen in recovery from radiation injury in mice. 3. Effect of splenectomy on survival of mice with spleen and bone marrow transplantation following lethal x-irradiation. Hiroshima J Med Sci (1966) 0.78
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood (1997) 4.51
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant (2001) 4.02
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94
Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant (2001) 3.35
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant (2002) 3.24
Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant (2007) 3.18
Social capital, income inequality, and firearm violent crime. Soc Sci Med (1998) 3.09
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med (1993) 2.90
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell (2001) 2.89
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
Giant-cell tumour of the tendon sheath. Is radiotherapy indicated to prevent recurrence after surgery? J Bone Joint Surg Br (2000) 2.54
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax (2013) 2.17
Association of single-stranded transferred DNA from Agrobacterium tumefaciens with tobacco cells. Proc Natl Acad Sci U S A (1994) 2.11
Problems of early infancy, formula changes, and mothers' beliefs about their infants. J Pediatr (1985) 2.09
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant (2002) 2.06
Severe and common side-effects of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant (1998) 2.05
Risk factors influencing the treatment outcome in diabetic macular oedema. Indian J Ophthalmol (1996) 2.03
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
A simplified method of CD34+ cell determination for peripheral blood progenitor cell transplantation and correlation with clinical engraftment. Exp Hematol (1998) 1.96
Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost (2002) 1.96
Women's status and the health of women and men: a view from the States. Soc Sci Med (1999) 1.85
Management of posterior capsule tears. Surv Ophthalmol (2001) 1.85
Three-dimensional organization of the 30S ribosomal proteins from Escherichia coli. I. Preliminary classification of the proteins. Proc Natl Acad Sci U S A (1970) 1.85
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant (2001) 1.82
Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand J Immunol (1977) 1.82
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia (2009) 1.80
Observation scales to identify serious illness in febrile children. Pediatrics (1982) 1.78
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Purification and properties of a nuclear exoribonuclease from Ehrlich ascites tumor cells. Proc Natl Acad Sci U S A (1967) 1.77
Value of the C-reactive protein test in the differentiation of bacterial and viral pneumonia. J Pediatr (1978) 1.76
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Mothers' perceptions of problems of feeding and crying behaviors. A prospective study. Am J Dis Child (1985) 1.74
Tuberculosis of the foot. J Bone Joint Surg Br (1999) 1.73
Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest (1999) 1.72
Prospective study of primary anastomosis without colonic lavage for patients with an obstructed left colon. Br J Surg (1999) 1.72
Traumatic diaphragmatic hernia: tertiary centre experience. Hernia (2009) 1.69
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant (1990) 1.65
Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am J Emerg Med (2000) 1.63
Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database. Anaesthesia (2007) 1.62
Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant (2005) 1.61
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis (2007) 1.61
Community based study of reproductive tract infections among ever married women of reproductive age in a rural area of Haryana, India. J Commun Dis (1999) 1.60
Aerobic bacterial isolates from burn wound infections and their antibiograms--a five-year study. Burns (2004) 1.59
Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58
A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant (2005) 1.56
Fungal endophthalmitis after a single intravenous administration of presumably contaminated dextrose infusion fluid. Retina (2000) 1.56
No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56
The Boarders in the Emergency Department (BED) study. Emerg Med J (2008) 1.56
Sonographic evidence of ascites, pleura-pericardial effusion and gallbladder wall edema for dengue fever. Prehosp Disaster Med (2011) 1.55
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Safety education in a pediatric primary care setting. Pediatrics (1987) 1.55
Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol (1999) 1.55
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant (2006) 1.53
Petrol-inhalation dependence : a case report. Indian J Psychiatry (1998) 1.53
Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplant (2009) 1.52
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51
Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol (2001) 1.51
Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol (2000) 1.50
Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.50
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol (1995) 1.49
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
PCR-positive tubercular retinal vasculitis: clinical characteristics and management. Retina (2001) 1.48
Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev (2005) 1.47
Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant (2008) 1.46
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol (1993) 1.46
Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant (2001) 1.46
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.45
IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest (1999) 1.44
High-dose cytosine arabinoside therapy for refractory leukemia. Blood (1983) 1.44
Peritoneal encapsulation: a preoperative diagnosis is possible. Postgrad Med J (2001) 1.44
Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res (1998) 1.42
High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med (2000) 1.42
Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant (2000) 1.42
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol (1989) 1.41
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41
'A rose by any other name would smell as sweet', or would it? Bone Marrow Transplant (2013) 1.41
Corynebacterium striatum: a diphtheroid with pathogenic potential. Clin Infect Dis (1993) 1.41